Improved Cortisol Exposure-Time Profile and Outcome in Patients with Adrenal Insufficiency: A Prospective Randomized Trial of a Novel Hydrocortisone Dual-Release Formulation
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
CONTEXT: Patients with treated adrenal insufficiency (AI) have increased morbidity and mortality rate. Our goal was to improve outcome by developing a once-daily (OD) oral hydrocortisone dual-release tablet with a more physiological exposure-time cortisol profile. OBJECTIVE: The aim was to compare pharmacokinetics and metabolic outcome between OD and the same daily dose of thrice-daily (TID) dose of conventional hydrocortisone tablets. DESIGN AND SETTING: We conducted an open, randomized, two-period, 12-wk crossover multicenter trial with a 24-wk extension at five university hospital centers. PATIENTS: The trial enrolled 64 adults with primary AI; 11 had concomitant diabetes mellitus (DM). INTERVENTION: The same daily dose of hydrocortisone was administered as OD dual-release or TID. MAIN OUTCOME MEASURE: We evaluated cortisol pharmacokinetics. RESULTS: Compared with conventional TID, OD provided a sustained serum cortisol profile 0-4 h after the morning intake and reduced the late afternoon and the 24-h cortisol exposure. The mean weight (difference = -0.7 kg, P = 0.005), systolic blood pressure (difference = -5.5 mm Hg, P = 0.0001) and diastolic blood pressure (difference: -2.3 mm Hg; P = 0.03), and glycated hemoglobin (absolute difference = -0.1%, P = 0.0006) were all reduced after OD compared with TID at 12 wk. Compared with TID, a reduction in glycated hemoglobin by 0.6% was observed in patients with concomitant DM during OD (P = 0.004). CONCLUSION: The OD dual-release tablet provided a more circadian-based serum cortisol profile. Reduced body weight, reduced blood pressure, and improved glucose metabolism were observed during OD treatment. In particular, glucose metabolism improved in patients with concomitant DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, whereas this dual-release hydrocortisone preparation was shown to slightly reduce blood pressure and HbA1c (104), such results may not always be desirable in patients with PAI.”
From Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [104]
In the citing paper
“Dual and slowrelease formulations of cortisol may better mimic circadian hormone release (104) but do not mimic the physiological pulsatile release of cortisol.”
From Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [104]
In the citing paper
“In men with CAH, gonadal and reproductive function are often impaired due to primary gonadal failure from TARTs and/or secondary gonadal failure due to suppressed hypothalamicpituitary-gonadal axis as a consequence of high adrenal androgen concentrations (378,437,438,625).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [378]
In the citing paper
“The reported prevalence of TARTs in CAH ranges from 14% to 86% (437,634), with an average of 25% in adolescents, and 46% in men (378).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [378]
In the citing paper
“TARTs are benign testicular tumors typically found in males with classic CAH (378,437).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [378]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1992) · PubMed · Cited by 33,716
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402 · cited 1×
“Also, patients with hypopituitarism have a doubled standardized mortality rate (6, 7), and young adults with AI as part of their hypopituitarism have a 7-fold excessive mortality rate (8).”
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006 · cited 1×
“Also, patients with hypopituitarism have a doubled standardized mortality rate (6, 7), and young adults with AI as part of their hypopituitarism have a 7-fold excessive mortality rate (8).”
Self-citationVgontzas, A. N., Bixler, E. O., Lin, H.-M., Prolo, P., Mastorakos, G., Vela-Bueno, A., Kales, A., & Chrousos, G. P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7778 · Cited by 884 · cited 1×
“When targeting a physiological S-cortisol profile, it should also be considered that although collection of normative data has been done with care (27), there is still a concern that nighttime cortisol levels might be falsely high due to an arousal effect (stress) (28).”
(1984) · Medical Entomology and Zoology · Cited by 741
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“There is a delicate balance between the short-term benefits on well-being and the long-term adverse metabolic and cognitive impact of slight cortisol overexposure as seen in subclinical Cushing’s syndrome (23) and in users of moderate doses of synthetic glucocorticoids (24).”
Premature Mortality in Patients with Addison’s Disease: A Population-Based Study
Bergthorsdottir, R., Leonsson-Zachrisson, M., Odén, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0076 · Cited by 490 · cited 2×
“Studies in patients with AD have shown a more than double the standardized mortality rate (4, 5) despite contemporary optimal glucocorticoid replacement therapy.”
Self-citationRossi, R. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.4.1440 · Cited by 419 · cited 1×
“There is a delicate balance between the short-term benefits on well-being and the long-term adverse metabolic and cognitive impact of slight cortisol overexposure as seen in subclinical Cushing’s syndrome (23) and in users of moderate doses of synthetic glucocorticoids (24).”
Hahner, S., Loeffler, M., Bleicken, B., Drechsler, C., Milovanovic, D., Fassnacht, M., Ventz, M., Quinkler, M., & Allolio, B. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0884 · Cited by 346 · cited 2×
“This may be higher than reported in a previous cross-sectional survey (10) studying the frequency of adrenal crises only.”
Filipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0524 · Cited by 321 · cited 7×
“Oral hydrocortisone in daily divided doses is the most widely used glucocorticoid in cortisol replacement therapy (2, 3), but no formal studies of its safety and efficacy have been performed in patients with AI.”
InfluentialSelf-citation
Cited by
Items 301–328 of 328
Simpson, V., & Brooke, A. M. (2021) · Medicine · doi:10.1016/j.mpmed.2021.05.010
Tritos, N. A., & Klibanski, A. (2018) · Wiley eBooks · doi:10.1002/9781119374800.ch12
Auchus, R. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-385157-4.01204-5
Lang, K., & Hahner, S. (2014) · Springer eBooks · doi:10.1007/978-3-642-54676-1_28-1
Management of Adult Patients With Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
Grouthier, V., Dulon, J., Bachelot, A., & Touraine, P. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.66140-8
Kanazawa, K., Hijikata, M., Koga, S., & Kuwabara, K. (2023) · Research Square · doi:10.21203/rs.3.rs-3381184/v1
Diabetes Care in the Oncologic Population
Presswala, L. S., Farooki, A., & Flory, J. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_24
Disorders of the Adrenal Gland in Children and Adolescents
Katugampola, H., & Krone, N. P. (2023) · Endocrinology · doi:10.1007/978-3-030-18901-3_4-1
Kanazawa, K., Hijikata, M., Koga, S., & Kuwabara, K. (2024) · Cureus · doi:10.7759/cureus.61456 · Cited by 1
Betterle, C., Sabbadin, C., & Presotto, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00056-4
Disorders of the Adrenal Gland in Children and Adolescents
Katugampola, H., & Krone, N. P. (2024) · Endocrinology · doi:10.1007/978-3-030-23709-7_4
Management of adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Grouthier, V., Dulon, J., Bachelot, A., & Touraine, P. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00132-1
Steroid replacement in adrenal insufficiency
Blair, J., Debono, M., & Ross, R. J. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00147-3
Simpson, V., & Brooke, A. M. (2025) · Medicine · doi:10.1016/j.mpmed.2025.06.011
Sungar, N. R., & Srinivasan, B. (2025) · Cureus · doi:10.7759/cureus.90553
Diabète de type 1 et insuffisance surrénale : une association maléfique
Reznik, Y. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2025.07.009
Kanazawa, K., Hijikata, M., & Kuwabara, K. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.10.010
Hypopituitarism, causes, diagnosis, management and mortality
Fountas, A., Effraimidis, G., & Karavitaki, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00308-3 · Cited by 1
Bandeira de Santana, L., de Souza Lima, T. A., Costa, A. R., Sandoval, L. A. M., de Souza, T. Y., da Mota, L. M. H., & Naves, L. A. (2024) · Figshare · doi:10.6084/m9.figshare.26758670
Choudhury, S., Lazarus, K., Sharma, A., Narula, K., Go, C., Cro, S., Thaventhiran, T., Khoo, B. C. E., Tan, T., & Meeran, K. M. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.2982 · Cited by 2
Yu, K., & Bancos, I. (2026) · Pituitary · doi:10.1007/s11102-026-01652-2
“Additionally, an RCT in PAI showed that dual-release hydrocortisone significantly reduced systolic and diastolic blood pressure compared with conven - tional therapy [ 5 ].”
InfluentialIglesias, P. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2649164 · Cited by 1
“…outcomes: a randomized trial of dual-release hydrocortisone reported improvements in weight and blood pressure versus conventional regimens [130], and the DREAM trial of once-daily modified-release hydrocortisone demonstrated beneficial metabolic signals (including glycemic indices)…”
Bima, C., Campioni, L., Berton, A. M., Sola, C., Bergoglio, B., Carlo, M. C. D., Ponzetto, F., Settanni, F., Ceccato, F., Parasiliti‐Caprino, M., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02874-8
“Consequently, salivary cortisol day-curves have been proposed as an alternative monitoring strategy, given that saliva sampling is non-invasive, stress-free, and easily repeatable [12, 22].”
Real-world outcomes with modified-release hydrocortisone in classic congenital adrenal hyperplasia
Auer, M. K., Bayer, K., Nowotny, H. F., Tschaidse, L., Dervishi, O., Welp, A.-C., Lottspeich, C., Bidlingmaier, M., Kunz, S. L., & Reisch, N. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag087
Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia
Goai, W. H., & Torpy, D. J. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2695099
“Administration of DRHC provides a rapid rise in cortisol followed by a sustained exposure throughout the day, but undetectable levels in the evening [43].”
Bonaventura, I., Weigand, I., Isidori, A. M., Kroiß, M., & Reincke, M. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag035
NING, C., Zhang, R., Liu, W., Zhou, X., Sun, Y., Han, X., Ji, L., & Ren, Q. (2026) · Endocrine Connections · doi:10.1530/ec-26-0304
Management of Endocrine Disorders and the Pharmacist's Role: Adrenal Insufficiency
Sweeting, A., & Chua, E. L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26472-6.00211-4
Metadata
- Authors
- Johannsson, G., Nilsson, A. G., Bergthorsdottir, R., Burman, P., Dahlqvist, P., Ekman, B., Engström, B. E., Olsson, T., Ragnarsson, O., Ryberg, M., Wahlberg, J., Biller, B. M. K., Monson, J. P., Stewart, P. M., Lennernäs, H., & Skrtic, S.
- Affiliations
- University of Gothenburg (SE)
- Skåne University Hospital (SE)
- Umeå University (SE)
- Linköping University (SE)
- Uppsala University Hospital (SE)
- Harvard University (US)
- St Bartholomew's Hospital (GB)
- University of Birmingham (GB)
- Uppsala University (SE)
- Corresponding author
- Johannsson, G.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-02
- Volume
- 97
- Issue
- 2
- Pages
- 473-481
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2108430953
- Semantic Scholar
- 89ffc7ce5ac189e54ea0a893bc1b71924fce41b3
- Cited by
- 329
- References
- 30
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 22 · 2023: 18 · 2022: 17 · 2021: 23 · 2020: 23 · 2019: 22 · 2018: 34 · 2017: 25 · 2016: 33 · 2015: 14 · 2014: 33 · 2013: 20 · 2012: 10
- FWCI
- 17.32
- Type
- journal article
- Language
- en
- Open access
- green
- lup.lub.lu.se
- Licence
- other-oa
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Forskningsrådet i Sydöstra Sverige
- National Institute for Health and Care Research (NF-SI-0508-10356)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- adrenal insufficiency, cortisol, once-daily dosing, HbA1c, glucose metabolism, diabetes mellitus, blood pressure, body weight, sustained-release tablets
- MeSH terms
- Adrenal Insufficiency, Adult, Aged, Chemistry, Pharmaceutical, Delayed-Action Preparations, Female, Humans, Hydrocortisone, Male, Middle Aged, Time Factors, Treatment Outcome, Cross-Over Studies, Area Under Curve, Metabolome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.